Cardiff Oncology, Inc.
CRDF
$4.00
$0.051.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.63% | -5.34% | -3.07% | -3.33% | -7.07% |
| Total Depreciation and Amortization | 1.51% | 7.87% | 17.46% | 38.98% | 68.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.00% | -0.96% | -22.84% | -14.84% | -28.64% |
| Change in Net Operating Assets | -51.71% | 22.19% | 122.09% | 192.68% | 1,828.42% |
| Cash from Operations | -22.04% | -4.31% | 1.84% | 7.02% | 8.67% |
| Capital Expenditure | 86.25% | 86.44% | 48.47% | 22.42% | 42.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.45% | -24.54% | 14.66% | 22.15% | -6.07% |
| Cash from Investing | -62.07% | -23.19% | 16.25% | 23.53% | -5.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 2,786.67% | 42.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 2,786.67% | 42.67% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 461.70% | 37.00% | 484.21% | 172.31% | 20.53% |
